PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

Dr. Jones is one of AIChE's 35 Under 35

The American Institute of Chemical Engineers (AIChE) has selected its latest group of engineers for their 35 Under 35 Award, and Dr. J...

PsyBio Therapeutics Announces Retention of Market Maker

PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic...

PsyBio Therapeutics Virtually Closes the Market

Evan Levine, Chief Executive Officer, PsyBio Therapeutics Corp. ("PsyBio" or "the Company") (TSXV: PSYB) and his team joined Dani Lipkin, Director, Global Business Development